Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, SUPERNUS PHARMACEUTICALS, INC. reported revenue of $719M, up 8.6% year over year. Operating margin was -8.7% and net margin -5.4%, on a free-cash-flow margin of 6.4% with capital expenditure at 0.2% of revenue. Every figure is computed directly from SUPN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $719M | -8.7% | -5.4% |
| FY2024 | $662M | 12.3% | 11.2% |
| FY2023 | $608M | -0.9% | 0.2% |
| FY2022 | $667M | 6.9% | 9.1% |
| FY2021 | $580M | 14.8% | 9.2% |
How does SUPN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.